Skip to main content
Top
Published in: Internal and Emergency Medicine 2/2021

01-03-2021 | Ticagrelor | IM - ORIGINAL

Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry

Authors: Felice Gragnano, Elisabetta Moscarella, Paolo Calabrò, Arturo Cesaro, Pia Clara Pafundi, Alfonso Ielasi, Giuseppe Patti, Ilaria Cavallari, Emilia Antonucci, Plinio Cirillo, Pasquale Pignatelli, Gualtiero Palareti, Francesco Pelliccia, Carlo Gaudio, Ferdinando Carlo Sasso, Vittorio Pengo, Paolo Gresele, Rossella Marcucci, the START-ANTIPLATELET Collaborators

Published in: Internal and Emergency Medicine | Issue 2/2021

Login to get access

Abstract

Optimal dual antiplatelet therapy (DAPT) strategy in high-bleeding risk (HBR) patients presenting with acute coronary syndrome remains debated. We sought to investigate the use of clopidogrel versus ticagrelor in HBR patients with acute coronary syndrome and their impact on ischemic and bleeding events at 1 year. In the START-ANTIPLATELET registry (NCT02219984), consecutive patients with ≥ 1 HBR criteria were stratified by DAPT type in clopidogrel versus ticagrelor groups. The primary endpoint was net adverse clinical endpoints (NACE), defined as a composite of all-cause death, myocardial infarction, stroke, and major bleeding. Of 1209 patients with 1-year follow-up, 553 were defined at HBR, of whom 383 were considered eligible for the study as on DAPT with clopidogrel (174 or 45.4%) or ticagrelor (209 or 54.6%). Clopidogrel was more often administered in patients at increased ischemic and bleeding risk, while ticagrelor in those undergoing percutaneous coronary intervention. Mean DAPT duration was longer in the ticagrelor group. At 1 year, after multivariate adjustment, no difference in NACEs was observed between patients on clopidogrel versus ticagrelor (19% vs. 11%, adjusted hazard ratio 1.27 [95% CI 0.71–2.27], p = 0.429). Age, number of HBR criteria, and mean DAPT duration were independent predictors of NACEs. In a real-world registry of patients with acute coronary syndrome, 45% were at HBR and frequently treated with clopidogrel. After adjustment for potential confounders, the duration of DAPT, but not DAPT type (stratified by clopidogrel vs. ticagrelor), was associated with the risk of ischemic and bleeding events at 1 year.
Appendix
Available only for authorised users
Literature
1.
go back to reference Valgimigli M, Bueno H, Byrne RA et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 39:213–254CrossRef Valgimigli M, Bueno H, Byrne RA et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 39:213–254CrossRef
2.
go back to reference Neumann F-J, Sousa-Uva M, Ahlsson A et al (2018) 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 40:87–165CrossRef Neumann F-J, Sousa-Uva M, Ahlsson A et al (2018) 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 40:87–165CrossRef
3.
go back to reference Crisci M, Gragnano F, Di Maio M et al (2019) Improving adherence to Ticagrelor in patients after acute coronary syndrome: results from the PROGRESS trial. Curr Vasc Pharmacol 18:294–301CrossRef Crisci M, Gragnano F, Di Maio M et al (2019) Improving adherence to Ticagrelor in patients after acute coronary syndrome: results from the PROGRESS trial. Curr Vasc Pharmacol 18:294–301CrossRef
4.
go back to reference Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057CrossRef Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057CrossRef
5.
go back to reference Eikelboom JW, Mehta SR, Anand SS et al (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114:774–782CrossRef Eikelboom JW, Mehta SR, Anand SS et al (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114:774–782CrossRef
6.
go back to reference Valgimigli M, Costa F, Lokhnygina Y et al (2017) Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 38:804–810PubMed Valgimigli M, Costa F, Lokhnygina Y et al (2017) Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 38:804–810PubMed
7.
go back to reference Urban P, Mehran R, Colleran R et al (2019) Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 40:2632–2653CrossRef Urban P, Mehran R, Colleran R et al (2019) Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 40:2632–2653CrossRef
8.
go back to reference Ueki Y, Bär S, Losdat S, et al (2020) Validation of bleeding risk criteria (ARC-HBR) in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention EIJ-D-20-00052 Ueki Y, Bär S, Losdat S, et al (2020) Validation of bleeding risk criteria (ARC-HBR) in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention EIJ-D-20-00052
9.
go back to reference Gragnano F, Cattano D, Calabrò P (2018) Perioperative care of cardiac patient’s candidate for non-cardiac surgery: a critical appraisal of emergent evidence and international guidelines. Intern Emerg Med 13:1185–1190CrossRef Gragnano F, Cattano D, Calabrò P (2018) Perioperative care of cardiac patient’s candidate for non-cardiac surgery: a critical appraisal of emergent evidence and international guidelines. Intern Emerg Med 13:1185–1190CrossRef
10.
go back to reference Prisco D (2018) A focus on direct oral anticoagulants: “old” and possible new indications and efforts for a better clinical management. Intern Emerg Med 13:985–988CrossRef Prisco D (2018) A focus on direct oral anticoagulants: “old” and possible new indications and efforts for a better clinical management. Intern Emerg Med 13:985–988CrossRef
11.
go back to reference Testa S, Ageno W, Antonucci E et al (2018) Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. Intern Emerg Med 13:1051–1058CrossRef Testa S, Ageno W, Antonucci E et al (2018) Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. Intern Emerg Med 13:1051–1058CrossRef
12.
go back to reference Alexopoulos D, Xanthopoulou I, Deftereos S et al (2016) Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry. J Thromb Haemost 14:1146–1154CrossRef Alexopoulos D, Xanthopoulou I, Deftereos S et al (2016) Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry. J Thromb Haemost 14:1146–1154CrossRef
13.
go back to reference Beigel R, Iakobishvili Z, Shlomo N et al (2017) Real-world use of novel P2Y12 inhibitors in patients with acute myocardial infarction: a treatment paradox. Cardiology 136:21–28CrossRef Beigel R, Iakobishvili Z, Shlomo N et al (2017) Real-world use of novel P2Y12 inhibitors in patients with acute myocardial infarction: a treatment paradox. Cardiology 136:21–28CrossRef
14.
go back to reference Sahlén A, Varenhorst C, Lagerqvist B et al (2016) Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish web system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Eur Hear J Cardiovasc Pharmacother 2:5–12CrossRef Sahlén A, Varenhorst C, Lagerqvist B et al (2016) Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish web system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Eur Hear J Cardiovasc Pharmacother 2:5–12CrossRef
15.
go back to reference Gragnano F, Fimiani F, Di Maio M et al (2019) Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. Intern Emerg Med 14:621–625CrossRef Gragnano F, Fimiani F, Di Maio M et al (2019) Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. Intern Emerg Med 14:621–625CrossRef
16.
go back to reference Patti G, Cavallari I, Antonucci E et al (2017) Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. PLoS ONE 12:e0186961CrossRef Patti G, Cavallari I, Antonucci E et al (2017) Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. PLoS ONE 12:e0186961CrossRef
17.
go back to reference Calabrò P, Moscarella E, Gragnano F et al (2019) Effect of body mass index on ischemic and bleeding events in patients presenting with acute coronary syndromes (from the START-ANTIPLATELET Registry). Am J Cardiol 124:1662–1668CrossRef Calabrò P, Moscarella E, Gragnano F et al (2019) Effect of body mass index on ischemic and bleeding events in patients presenting with acute coronary syndromes (from the START-ANTIPLATELET Registry). Am J Cardiol 124:1662–1668CrossRef
18.
go back to reference Calabrò P, Gragnano F, Di Maio M et al (2018) Epidemiology and management of patients with acute coronary syndromes in contemporary real-world practice: evolving trends from the EYESHOT study to the START-ANTIPLATELET registry. Angiology 69:795–802CrossRef Calabrò P, Gragnano F, Di Maio M et al (2018) Epidemiology and management of patients with acute coronary syndromes in contemporary real-world practice: evolving trends from the EYESHOT study to the START-ANTIPLATELET registry. Angiology 69:795–802CrossRef
19.
go back to reference Costa F, van Klaveren D, James S et al (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389:1025–1034CrossRef Costa F, van Klaveren D, James S et al (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389:1025–1034CrossRef
20.
go back to reference Garcia-Garcia HM, McFadden EP, Farb A et al (2018) Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document. Circulation 137:2635–2650CrossRef Garcia-Garcia HM, McFadden EP, Farb A et al (2018) Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document. Circulation 137:2635–2650CrossRef
21.
go back to reference Sacco RL, Kasner SE, Broderick JP et al (2013) An updated definition of stroke for the 21st century. Stroke 44:2064–2089CrossRef Sacco RL, Kasner SE, Broderick JP et al (2013) An updated definition of stroke for the 21st century. Stroke 44:2064–2089CrossRef
22.
go back to reference Jolly SS, Cairns JA, Yusuf S et al (2015) Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 372:1389–1398CrossRef Jolly SS, Cairns JA, Yusuf S et al (2015) Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 372:1389–1398CrossRef
23.
go back to reference Zocca P, Van Der Heijden LC, Kok MM et al (2017) Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT. EuroIntervention 13:1168–1176CrossRef Zocca P, Van Der Heijden LC, Kok MM et al (2017) Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT. EuroIntervention 13:1168–1176CrossRef
24.
go back to reference Zocca P, Kok MM, van der Heijden LC et al (2018) High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: insights from CHANGE DAPT. Int J Cardiol 268:11–17CrossRef Zocca P, Kok MM, van der Heijden LC et al (2018) High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: insights from CHANGE DAPT. Int J Cardiol 268:11–17CrossRef
25.
go back to reference De Luca L, De Servi S, Musumeci G, Bolognese L (2018) Is ticagrelor safe in octogenarian patients with non-ST elevation acute coronary syndromes? Eur Heart J Cardiovasc Pharmacother 4:12–14CrossRef De Luca L, De Servi S, Musumeci G, Bolognese L (2018) Is ticagrelor safe in octogenarian patients with non-ST elevation acute coronary syndromes? Eur Heart J Cardiovasc Pharmacother 4:12–14CrossRef
26.
go back to reference De Luca L, Zeymer U, Claeys MJ, et al (2020) Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries. Eur Heart J Cardiovasc Pharmacother 22; pvaa002 De Luca L, Zeymer U, Claeys MJ, et al (2020) Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries. Eur Heart J Cardiovasc Pharmacother 22; pvaa002
27.
go back to reference Li L, Geraghty OC, Mehta Z, Rothwell PM (2017) Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 390:490–499CrossRef Li L, Geraghty OC, Mehta Z, Rothwell PM (2017) Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 390:490–499CrossRef
28.
go back to reference Porta L, Baorda F, Fusco A, Gruppo di Autoformazione Metodologica (GrAM) (2018) Is proton pump inhibitors’ prophylaxis indicated for patients on antiplatelet therapy? Intern Emerg Med 13:585–587CrossRef Porta L, Baorda F, Fusco A, Gruppo di Autoformazione Metodologica (GrAM) (2018) Is proton pump inhibitors’ prophylaxis indicated for patients on antiplatelet therapy? Intern Emerg Med 13:585–587CrossRef
29.
go back to reference Valgimigli M, Frigoli E, Leonardi S et al (2018) Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet 392:835–848CrossRef Valgimigli M, Frigoli E, Leonardi S et al (2018) Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet 392:835–848CrossRef
30.
go back to reference Bianchi R, D’Acierno L, Crisci M et al (2017) From femoral to radial approach in coronary intervention. Angiology 68:281–287CrossRef Bianchi R, D’Acierno L, Crisci M et al (2017) From femoral to radial approach in coronary intervention. Angiology 68:281–287CrossRef
31.
go back to reference Gragnano F, Manavifar N, Gargiulo G et al (2019) Femoral access with or without vascular closure device or radial access in acute coronary syndrome. JACC Cardiovasc Interv 12:2116–2118CrossRef Gragnano F, Manavifar N, Gargiulo G et al (2019) Femoral access with or without vascular closure device or radial access in acute coronary syndrome. JACC Cardiovasc Interv 12:2116–2118CrossRef
32.
go back to reference Gragnano F, Calabrò P, Valgimigli M (2019) Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? Eur Heart J 40:216–217CrossRef Gragnano F, Calabrò P, Valgimigli M (2019) Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? Eur Heart J 40:216–217CrossRef
Metadata
Title
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry
Authors
Felice Gragnano
Elisabetta Moscarella
Paolo Calabrò
Arturo Cesaro
Pia Clara Pafundi
Alfonso Ielasi
Giuseppe Patti
Ilaria Cavallari
Emilia Antonucci
Plinio Cirillo
Pasquale Pignatelli
Gualtiero Palareti
Francesco Pelliccia
Carlo Gaudio
Ferdinando Carlo Sasso
Vittorio Pengo
Paolo Gresele
Rossella Marcucci
the START-ANTIPLATELET Collaborators
Publication date
01-03-2021
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 2/2021
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-020-02404-1

Other articles of this Issue 2/2021

Internal and Emergency Medicine 2/2021 Go to the issue